11:43 AM EST - Resverlogix Corp. : has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment of Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, "Methods of Preparing Quinazolinone Derivatives" was granted until June 2029. Resverlogix Corp.
shares T.RVX are trading up $0.14 at $1.70.
